Background
Methods
Patients and ART
Number of patients | |||
---|---|---|---|
Variables | Adults | Children | |
WHO clinical stage | |||
I | 3 | 4 | |
II | 11 | 6 | |
III | 72 | 57 | |
IV | 14 | 33 | |
Anaemia status (%)a
| |||
Anaemic | 62 | 67 | |
Non anaemic | 38 | 33 | |
CD4 cell count (cells/mm3)b
| |||
<50 | 6 | 0 | |
50-99 | 25 | 5 | |
100-199 | 55 | 14 | |
200-349 | 14 | 33 | |
≥350 | 0 | 48 | |
Total duration on ART (months) | |||
13-24 | 100 | 100 | |
25-36 | 47 | 56 | |
37-48 | 13 | 23 | |
49-60 | 4 | 15 | |
≥61 | 0 | 5 | |
ART regimen | |||
1a: 3TC + d4T + NVP | 39 | 57 | |
1b: 3TC + d4T + EFV | 32 | 5 | |
1c: 3TC + AZT** + NVP | 17 | 35 | |
1d: 3TC + AZT + EFV*** | 12 | 3 |
Study design and selection procedure
Clinical and laboratory assessment
RNA extraction and plasma viral load determination
Sequence determination of HIV-1 pol gene
Statistical analysis
Ethical issues
Results
Baseline patient’s characteristics
Virological response to ART
Code | ART regimenb
| Time on ART | PVLc
| Mutations | Subtype | |
---|---|---|---|---|---|---|
(months) | PR | RT | ||||
0053 | 1a/1c | 40 | 13945 | M36I, H69K, T74S, L89M | - | C |
1959 | 1c | 26 | 598 | M36I, H69K, T74S, L89M | - | C |
3438 | 1d | 13 | 495 | M36I, H69K, L89M | - | C |
1739 | 1b | 25 | 18239 | M36I, H69K, L89M | K103N | C |
2369 | 1c | 19 | 25678 | M36I, H69K, L89M | M41L, L210W | C |
CD4+T cell response to ART
Effect of baseline CD4+ T cell count and ART regimens on rates of CD4+T cell increase
Variables |
aRisk of non-response |
bRisk of failure to attain >200 CD4 cell | |||
---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | ||
Sex | Female | 0.2 (0.65-0.658) | 0.08 | 6.5 | |
Male | 0.4 (0.16-1.33) | 0.150 | |||
Age (years) | <29 | 0.76 | 0.52 | ||
30-39 | 1.68 (0.401-7.09) | 0.47 | 14.0 (1.62-122.7) | 0.160 | |
≥40 | 1.17 (0.32-4.21) | 0.81 | 1.88 (0.60-5.90) | 0.278 | |
WHO Clinical Stage I | I | 0.69 | 0.4 | ||
II | 0.154 (0.007-3.57) | 0.244 | 0.038 (0.002-0.894) | 0.045 | |
III | 0.346 (0.027-4.418 | 0.414 | 0.769 (0.043-13.866) | 0.8 | |
IV | 0.359 (0.043-3.013) | 0.345 | 0.325 (0.039-2.7) | 0.32 | |
Haematocrit value | < 37% | 3.0 | 3.0 | ||
≥ 37% | 2.54 (0.848-7.514) | 0.096 | 2.16 (0.751-6.253) | 0.153 | |
ART regimen | |||||
3TC + d4T + NVP | 1.66 (0.349-7.9) | 0.542 | 4.857 (0.974-24.227) | 0.054 | |
3TC + d4T + EFV | 1.87 (0.36-9.64) | 0.450 | 2.286 (0.50-10.44) | 0.286 | |
3TC + AZT + NVP | 6.00 (0.53-67.27) | 0.146 | 2.667 (0.463-15.35) | 0.272 | |
3TC + AZT + EFV | 0.54 | 0.288 | |||
CD4+ T cell count | <50 | 0.313 | 0.99 | ||
50-99 | 2.00 (0.174-22.94) | 0.578 | 0.578 0.99 (0.00-) | 0.9 | |
100-199 | 9.20 (0.91-93.02) | 0.060 | 0.060 0.99 (0.00-) | 0.9 | |
200-349 | 1.68 (0.436-6.47) | 0.451 | 0.451 0.99 (0.00-) | 0.9 |